Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Alternate Dosing Schedules Study for HPV Vaccine (ADS) (ADS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02280642
Recruitment Status : Completed
First Posted : October 31, 2014
Last Update Posted : October 31, 2014
Sponsor:
Collaborator:
Centers for Disease Control and Prevention
Information provided by (Responsible Party):
Duke University

Brief Summary:

The purpose of this study was to determine if delayed dosing of recombinant human papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls elicited an equivalent immune response (geometric mean titers to HPV 6,11,16, and 18 as measured one month after receipt of a 3rd dose of HPV vaccine) when compared to vaccine delivered according to the recommended dosing schedule.

This was a prospective observational study of healthy 9-18 year old female patients receiving either a second or third dose of HPV vaccine as part of their well child care. Immune responses to HPV types 6, 11, 16 and 18 were measured both before and 1 month after the third dose of HPV vaccine with the purpose of comparing the immune responses to HPV vaccine when administered at naturally occurring longer dosing intervals to the immune response to HPV vaccine when administered as routinely recommended.

In addition, girls receiving a 3rd dose of HPV vaccine as well as concomitantly administered vaccines by injection were randomized to receive either the HPV vaccine first or their concomitantly administered vaccines first. Pain following vaccination was assessed in each arm using the Faces Pain Scale - Revised.

Please note: This record refers only to the observational portion of the study. Please refer to NCT00862810 for the results of the randomized portion of the study.


Condition or disease Intervention/treatment
Cervical Cancer Genital Warts Biological: Both 2nd and 3rd doses on time Biological: 2nd dose late and 3rd dose on time Biological: 2nd dose on time and 3rd dose late Biological: Both doses late

Layout table for study information
Study Type : Observational
Actual Enrollment : 331 participants
Time Perspective: Prospective
Official Title: Alternate Dosing Schedules Study for HPV Vaccine
Study Start Date : March 2009
Actual Primary Completion Date : September 2012
Actual Study Completion Date : September 2012

Group/Cohort Intervention/treatment
Both doses on time
An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.
Biological: Both 2nd and 3rd doses on time
Dose 2 delayed
A delayed dose 2 was defined as > 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.
Biological: 2nd dose late and 3rd dose on time
Dose 3 delayed
An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2.
Biological: 2nd dose on time and 3rd dose late
Both doses delayed
A delayed dose 2 was defined as > 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2.
Biological: Both doses late



Primary Outcome Measures :
  1. HPV 6 GMT [ Time Frame: 1 month following 3rd dose of HPV vaccine ]
    Geometric mean titer (GMT) of antibody to HPV type 6

  2. HPV 11 GMT [ Time Frame: 1 month following 3rd dose of HPV vaccine ]
    Geometric mean titer (GMT) of antibody to HPV type 11

  3. HPV 16 GMT [ Time Frame: 1 month following 3rd dose of HPV vaccine ]
    Geometric mean titer (GMT) of antibody to HPV type 16

  4. HPV 18 GMT [ Time Frame: 1 month following 3rd dose of HPV vaccine ]
    Geometric mean titer (GMT) of antibody to HPV type 18


Biospecimen Retention:   Samples Without DNA
Serum


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   9 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Adolescent females attending primary care clinics in central North Carolina
Criteria

Inclusion Criteria:

  1. A healthy, medically well female between the ages of 9 - 18 years. (Must be between 9 years and younger than 19 years of age) at time of enrollment
  2. Must be receiving either a 3rd dose of HPV vaccine (All Groups) or a 2nd dose of HPV vaccine (Group 2 only)

    • For Group 1 - EITHER 1) The second dose of HPV vaccine must not have been administered and it must be within the specified dosing interval for the second dose of HPV vaccine (> 90 days since the first dose of HPV vaccine) OR 2) The second dose of HPV vaccine must have been administered > 90 days after the first dose of HPV vaccine and it must be within the specified dosing interval for the third dose of HPV vaccine (> 60 days - < 180 days since the second dose of HPV)
    • For Group 2 - The second dose of HPV vaccine must have been administered > 30 days and < 90 days after the first dose of HPV vaccine and it must be within the specified dosing interval for the third dose (> 180 days since the second dose of HPV)
    • For Group 3 - The second dose of HPV vaccine must have been administered > 30 days and < 90 days after the first dose of HPV vaccine and it must be within the specified dosing interval for the third dose (> 60 days - < 180 days since the second dose of HPV)
    • For Group 4- The second dose of HPV vaccine must have been administered > 90 days after the first dose of HPV of HPV vaccine and it must be within the specified dosing interval for the third dose (> 180 days since the second dose of HPV)
  3. Ability and willingness to participate in the study by providing written informed assent. Verbal assent is acceptable for subjects less than 12 years of age.
  4. Parent/guardian provides informed consent
  5. Anticipated ability and willingness to complete all study visits and evaluations

Exclusion Criteria:

  1. Unable to comply with the study protocol
  2. Receipt of three or more doses of HPV vaccine or receipt of doses of HPV vaccine outside the pre-specified time windows
  3. Receipt of blood and or blood products (including immunoglobulin) in the past 3 months or anticipated receipt during the study period
  4. Receipt of a live virus vaccine (varicella virus containing vaccine, any measles, mumps, or rubella virus containing vaccine such as MMR, or yellow fever vaccine but not including live attenuated influenza virus vaccine) within 4 weeks of receipt of the 3rd dose of HPV vaccine or anticipated receipt of a live virus vaccine within 4 weeks after the 3rd dose of HPV vaccine
  5. History of any physical, mental, or developmental disorder that study personnel believe may hinder a participant's ability to comply with the study requirements
  6. History of malignancy or confirmed or suspected immunodeficient condition such as HIV infection
  7. Receipt of or history of receipt of any medications or treatments that affect the immune system, such as immune globulin, interferon, immunomodulators, cytotoxic drugs or other drugs known to be frequently associated with significant major organ toxicity since six months prior to the first HPV vaccine dose. Receipt of long-term (greater than or equal to 2 weeks) potentially immunosuppressive corticosteroid use within six months prior to HPV vaccine dose 1 and enrollment or anticipated receipt during the study period. Specifically, potentially immunosuppressive corticosteroids are any parenteral corticosteroid, high dose (>800 mcg/day) beclomethasone dipropionate or equivalent medication. Nasal and topical steroids are allowed.
  8. Current or former participation in HPV vaccine related research.
  9. Receipt of an investigational or alternate HPV vaccine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02280642


Locations
Layout table for location information
United States, North Carolina
Chapel Hill Pediatrics
Chapel Hill, North Carolina, United States, 27514
Duke Children's Primary Care
Durham, North Carolina, United States, 27704
Durham Pediatrics
Durham, North Carolina, United States, 27704
Sponsors and Collaborators
Duke University
Centers for Disease Control and Prevention
Investigators
Layout table for investigator information
Principal Investigator: Emmanuel B Walter, MD Duke University

Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT02280642     History of Changes
Other Study ID Numbers: Pro00014388_1
CDC#U36/CCU319276 CFDA 93.283
First Posted: October 31, 2014    Key Record Dates
Last Update Posted: October 31, 2014
Last Verified: October 2014
Keywords provided by Duke University:
Human papillomavirus
Cervical cancer
Genital warts
Vaccine
Immunogenicity
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Diseases
Vaccines
Condylomata Acuminata
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female
Warts
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases
Immunologic Factors
Physiological Effects of Drugs